



# HHS Public Access

Author manuscript

*J Natl Compr Canc Netw*. Author manuscript; available in PMC 2016 August 08.

Published in final edited form as:

*J Natl Compr Canc Netw*. 2015 July ; 13(7): 847–856.

## Head and Neck Cancers, Version 1.2015:

### Featured Updates to the NCCN Guidelines

David G. Pfster, MD<sup>1</sup>, Sharon Spencer, MD<sup>2,\*</sup>, David M. Brizel, MD<sup>3</sup>, Barbara Burtness, MD<sup>4</sup>, Paul M. Busse, MD, PhD<sup>5</sup>, Jimmy J. Caudell, MD, PhD<sup>6</sup>, Anthony J. Cmelak, MD<sup>7</sup>, A. Dimitrios Colevas, MD<sup>8</sup>, Frank Dunphy, MD<sup>3</sup>, David W. Eisele, MD<sup>9</sup>, Robert L. Foote, MD<sup>10,\*</sup>, Jill Gilbert, MD<sup>7</sup>, Maura L. Gillison, MD, PhD<sup>11</sup>, Robert I. Haddad, MD<sup>12</sup>, Bruce H. Haughey, MBChB, MS<sup>13</sup>, Wesley L. Hicks Jr, MD<sup>14</sup>, Ying J. Hitchcock, MD<sup>15</sup>, Antonio Jimeno, MD, PhD<sup>16</sup>, Merrill S. Kies, MD<sup>17</sup>, William M. Lydiatt, MD<sup>18</sup>, Ellie Maghami, MD<sup>19</sup>, Thomas McCaffrey, MD, PhD<sup>6</sup>, Loren K. Mell, MD<sup>20</sup>, Bharat B. Mittal, MD<sup>21</sup>, Harlan A. Pinto, MD<sup>8</sup>, John A. Ridge, MD, PhD<sup>22</sup>, Cristina P. Rodriguez, MD<sup>23</sup>, Sandeep Samant, MD<sup>24</sup>, Jatin P. Shah, MD, PhD<sup>1</sup>, Randal S. Weber, MD<sup>17</sup>, Gregory T. Wolf, MD<sup>25</sup>, Frank Worden, MD<sup>25</sup>, Sue S. Yom, MD, PhD<sup>26,\*</sup>, Nicole McMillian, MS<sup>27,\*</sup>, and Miranda Hughes, PhD<sup>27,\*</sup>

<sup>1</sup>Memorial Sloan Kettering Cancer Center

<sup>2</sup>University of Alabama at Birmingham Comprehensive Cancer Center

<sup>3</sup>Duke Cancer Institute

<sup>4</sup>Yale Cancer Center/Smilow Cancer Hospital

<sup>5</sup>Massachusetts General Hospital Cancer Center

---

The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN.

\*Provided content development and/or authorship assistance.

**Disclosure of Relevant Financial Relationships: Editor: Kerrin M. Green, MA**, Assistant Managing Editor, *JNCCN—Journal of the National Comprehensive Cancer Network*, has disclosed that she has no relevant financial relationships.

**CE Planners: Deborah J. Moonan, RN, BSN**, Director, Continuing Education, NCCN, has disclosed that she has no relevant financial relationships.

**Ann Gianola, MA**, Manager, Continuing Education Accreditation & Program Operations, NCCN, has disclosed that she has no relevant financial relationships.

**Kristina M. Gregory, RN, MSN, OCN**, Vice President, Clinical Information Operations, NCCN, has disclosed that she has no relevant financial relationships.

**Rashmi Kumar, PhD**, Senior Manager, Clinical Content, NCCN, has disclosed that she has no relevant financial relationships.

**Individuals Who Provided Content Development and/or Authorship Assistance: Sharon Spencer, MD**, Panel Vice-Chair, has disclosed that she has no relevant financial relationships.

**Robert L. Foote, MD**, Panel Member, has disclosed that is a chapter author and receives royalties from UpToDate.

**Sue S. Yom, MD, PhD**, Panel Member, has disclosed that she receives clinical trial research support from Genentech Inc.

**Nicole McMillian, MS**, Guidelines Coordinator, NCCN, has disclosed that she has no relevant financial relationships.

**Miranda Hughes, PhD**, Oncology Scientist/Senior Medical Writer, NCCN, has disclosed that she has no relevant financial relationships.

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup>®</sup>) are a statement of consensus of the authors regarding their views of currently accepted approaches to treatment. The NCCN Guidelines<sup>®</sup> Insights highlight important changes to the NCCN Guidelines<sup>®</sup> recommendations from previous versions. Colored markings in the algorithm show changes and the discussion aims to further the understanding of these changes by summarizing salient portions of the NCCN Guideline Panel discussion, including the literature reviewed.

These NCCN Guidelines Insights do not represent the full NCCN Guidelines; further, the National Comprehensive Cancer Network<sup>®</sup> (NCCN<sup>®</sup>) makes no representation or warranties of any kind regarding the content, use, or application of the NCCN Guidelines and NCCN Guidelines Insights and disclaims any responsibility for their applications or use in any way.

The full and most current version of these NCCN Guidelines are available at NCCN.org.

<sup>6</sup>Moffitt Cancer Center

<sup>7</sup>Vanderbilt-Ingram Cancer Center

<sup>8</sup>Stanford Cancer Institute

<sup>9</sup>The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

<sup>10</sup>Mayo Clinic Cancer Center

<sup>11</sup>The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute

<sup>12</sup>Dana-Farber/Brigham and Women's Cancer Center

<sup>13</sup>Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

<sup>14</sup>Roswell Park Cancer Institute

<sup>15</sup>Huntsman Cancer Institute at the University of Utah

<sup>16</sup>University of Colorado Cancer Center

<sup>17</sup>The University of Texas MD Anderson Cancer Center

<sup>18</sup>Fred & Pamela Buffett Cancer Center

<sup>19</sup>City of Hope Comprehensive Cancer Center

<sup>20</sup>UC San Diego Moores Cancer Center

<sup>21</sup>Robert H. Lurie Comprehensive Cancer Center of Northwestern University

<sup>22</sup>Fox Chase Cancer Center

<sup>23</sup>Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance

<sup>24</sup>St. Jude Children's Research Hospital/The University of Tennessee Health Science Center

<sup>25</sup>University of Michigan Comprehensive Cancer Center

<sup>26</sup>UCSF Helen Diller Family Comprehensive Cancer Center

<sup>27</sup>National Comprehensive Cancer Network

## Abstract

These NCCN Guidelines Insights focus on recent updates to the 2015 NCCN Guidelines for Head and Neck (H&N) Cancers. These Insights describe the different types of particle therapy that may be used to treat H&N cancers, in contrast to traditional radiation therapy (RT) with photons (x-ray). Research is ongoing regarding the different types of particle therapy, including protons and carbon ions, with the goals of reducing the long-term side effects from RT and improving the therapeutic index. For the 2015 update, the NCCN H&N Cancers Panel agreed to delete recommendations for neutron therapy for salivary gland cancers, because of its limited availability, which has decreased over the past 2 decades; the small number of patients in the United States who currently receive this treatment; and concerns that the toxicity of neutron therapy may offset potential disease control advantages.

## Overview

More than 600,000 cases of head and neck (H&N) cancers occur worldwide, with 300,000 patients dying of the disease each year.<sup>1</sup> The incidence of human papilloma virus (HPV)–related oropharyngeal cancers is increasing, but this specific subset of H&N cancers is associated with improved survivorship and increased long-term survival.<sup>2–7</sup> More than 11,000 new cases of HPV-related H&N cancers occur each year in the United States, with progression-free survival rates anticipated to be more than 85% in patients with a minimal history of smoking.<sup>8</sup> It is important to continue to maintain the excellent rates of disease control obtained in these certain classes of H&N cancers; however, for all patients with H&N cancers, it is equally important to minimize the acute effects of their therapies and the late effects in long-term survivors.

Over the past 15 years, intensity-modulated radiotherapy (IMRT) has displaced other techniques in the treatment of most H&N malignancies.<sup>9–15</sup> Reports indicate that xerostomia has decreased because of the transition to IMRT from older 2-dimensional and 3-dimensional radiotherapy techniques,<sup>9,11</sup> but there are likely some tradeoffs as a result of low-dose redistribution to other surrounding normal tissues. For example, IMRT can create new, unexpected acute toxicities to organs radiated in the beam path.<sup>16,17</sup> In addition, the long-term effects, even with using IMRT, can still result in a substantial decrease in quality of life.<sup>18–23</sup> Few long-term studies of IMRT outcomes are available for longer than 2 to 5 years, but older studies quantify the long-term effects of conventional forms of radiation therapy (RT), either alone or in conjunction with concurrent chemoradiation.<sup>21,24</sup> For example, RTOG 95-01 included patients with oral cavity, oropharyngeal, laryngeal, or hypopharyngeal cancer; the rates of grade 3 to 5 toxicity were 24.9% for patients receiving chemoradiation versus 20.5% for RT alone after more than 9 years.<sup>24</sup> RTOG 91-11 included patients with locally advanced laryngeal cancer; the rates of grade 3 to 5 toxicity were 33% for patients receiving concurrent chemoradiation versus 38% for RT alone after 10 years.<sup>21</sup> Although the toxicity rates of concurrent chemoradiation versus RT alone were not statistically different in either trial, clinicians remain concerned about the potential incremental toxicity burden of adding concurrent chemotherapy to radiation over the very long term that may not be fully measured. Understandably, investigating ways to decrease the long-term toxicity burden from therapy, either radiation alone or concurrent chemoradiation, is a research priority.<sup>15</sup>

### Principles Of Radiation Therapy<sup>1</sup>

#### DEFINITIVE

##### RT Alone

- Photon or photon/electron therapy or highly conformal radiation therapy techniques
- PTV:
  - High risk: Primary tumor and involved lymph nodes (this includes possible local subclinical infiltration at the primary and at the high-risk level lymph node(s))
  - ◆ Fractionation:

	•	66 Gy (2.0 Gy/fraction) to 70-70.2 Gy (1.8-2.0 Gy/fraction); daily Monday-Friday in 6-7 weeks <sup>2</sup>
–		Low to intermediate risk: Sites of suspected subclinical spread
	◆	44-50 Gy (2.0 Gy/fraction) to 54-63 Gy (1.6-1.8 Gy/fraction) <sup>3</sup>
<u>POSTOPERATIVE</u>		
RT		
•		Preferred interval between resection and postoperative RT is 6 weeks
•		Photon or photon/electron therapy
•		PTV
–		High risk: Adverse features such as positive margins (see SALI-3)
	◆	60-66 Gy (2.0 Gy/fraction); daily Monday-Friday in 6-7 weeks
–		Low to intermediate risk: Sites of suspected subclinical spread
	◆	44-50 Gy (2.0 Gy/fraction) to 54-63 Gy (1.6-1.8 Gy/fraction) <sup>3</sup>
Either intensity-modulated RT (IMRT) or 3-D conformal RT is recommended.		

<sup>1</sup> See Radiation Techniques (RAD-A) and (Discussion).

<sup>2</sup> For doses >70 Gy, some clinicians feel that the fractionation should be slightly modified (eg, <2.0 Gy/fraction for at least some of the treatment) to minimize toxicity. An additional 2–3 doses can be added depending on the clinical circumstances.

<sup>3</sup> Suggest 44–50 Gy in conformal RT and sequentially planned IMRT or 54–63 Gy with IMRT doser painting technique dependent on dose per fraction).

Most traditional RT therapy uses ionizing photon beams (x-rays). However, particle therapy, including protons, neutrons, and carbon ions, has also been investigated in an effort to decrease acute and late RT toxicities.<sup>25,26</sup> Several commercial machines for particle therapy have only become available in the past decade; therefore, the clinical experience using particle therapies to treat H&N cancers remains limited. Currently, whether particle therapies will significantly decrease acute and long-term toxicity for patients with H&N cancers or whether they will produce equivalent or different rates of tumor control is unknown. A major hindrance at this time to large-scale exploration of particle therapies is that great financial cost is associated with installation of commercial machines for particle therapy and their continued operations.<sup>27</sup> One facility serving a pediatric population reported that two-thirds of their patients received treatment at a financial loss because of the payer mix and decreased reimbursement; patients were nonetheless treated with proton therapy based on a belief in the potential favorable outcomes that would occur in the pediatric population.<sup>28</sup>

Neutron therapy was removed from the pathways for salivary gland cancers in the 2015 version of the NCCN Guidelines for H&N Cancers because of the extreme limitation on the availability of this treatment—one center only in the United States—and its consequently restricted clinical application (see SALI-A, page 849). Although the potential clinical value of neutron therapy for selected cases is recognized, there are lingering toxicity concerns regarding its use, and the NCCN Guidelines are meant to apply to more than 5% of the eligible patients. Although carbon ion therapy is not currently available in the United States,

it is available in Germany and Japan<sup>29</sup>; a few US-based centers are in the early phases of exploration and development of carbon ion therapy. These 3 specific particle therapies, including protons, neutrons, and carbon ions, are described in these NCCN Guidelines Insights. The full version of the NCCN Guidelines for H&N Cancers address all aspects of management for the different types of H&N cancers, including diagnosis, evaluation, staging, primary treatment, surveillance, and therapy for recurrence and metastasis. For a list of all recent revisions, see the “Summary of the Guidelines Updates” in the complete version of these guidelines at NCCN.org.

## Particle Therapies

### Neutron Therapy

Neutrons were the first high-linear energy transfer (LET) particles used in clinical RT. The high LET and low oxygen enhancement ratio (OER) of neutrons led physicians to believe that these particles would yield a clinical benefit for cancer therapy. In 1977, results were reported in 133 patients with locally advanced cancers of the H&N. The local control was favorable, and the complications were reported as acceptable.<sup>30</sup> Other promising results finally led to the establishment of other neutron centers around the world. Several neutron therapy trials were associated with reasonable control rates in tumors that were considered to be locally advanced.<sup>31,32</sup> The Edinburgh trial and other multi-institutional trials for H&N cancers reported control rates ranging from 32% to 45%. However, the late effects were somewhat alarming, with late grade 3 to 5 toxicities of up to 40%.<sup>33</sup> The RTOG and Medical Research Council (MRC) conducted a trial for salivary gland tumors comparing fast neutron versus photon therapy. The trial included 25 patients with locally advanced disease. The local control at 10 years was 56% versus 17% in favor of neutron therapy, but no improvement in survival was seen.<sup>34</sup> The pooled analyses of several studies confirmed local control benefits with neutron therapy when compared with photon therapy for advanced salivary gland cancers.<sup>34,35</sup> However, the risk of late effects was high and generally found to continue to increase over time, reaching as much as 20% at 9 years.<sup>34,36</sup> Increased complications were thought to be related to variations in the relative biologic effectiveness (RBE) of neutron therapy and the impact on late responding tissues.<sup>7,37,38</sup> Notably, the efficacy advantage of neutrons compared with photons seemed to be best established for salivary gland cancers. A Cochrane Collaboration systematic review evaluating the efficacy of radiotherapy interventions for oral cavity and oropharyngeal cancer failed to demonstrate any significant difference in survival or disease-control outcomes between neutron and photon therapy.<sup>39</sup>

Arguably, in a field dominated by uncontrolled studies, the RTOG-MRC randomized trial played a critical role in establishing neutron therapy as a potentially more efficacious option for unresectable salivary gland cancers. That being said, it deserves emphasis that by contemporary standards, the RTOG-MRC study had significant methodological limitations that should be considered when interpreting the disease control and survival results. The sample size was small; the distribution of histologic subtypes was heterogeneous and not fully balanced (eg, 23% of the patients on the neutron arm had acinic cell carcinoma vs 0% of patients on the photon arm); and other prognostically relevant factors (eg, resectability,

primary versus recurrent disease, tumor size) also varied somewhat between treatment arms. These limitations likely had a smaller impact on the toxicity data, which noted a higher incidence of severe morbidity on the neutron arm ( $P=.07$ ).

These findings and limitations (ie, concerns that the toxicity of neutron therapy may offset potential disease control advantages) decreased the enthusiasm for neutron therapy research. At one point, there were 8 active neutron centers in the United States; however, almost all of these centers have now closed. The number of centers in Europe has also decreased. However, the neutron center at the University of Washington Medical Center is still open in the United States and is treating a small number of patients with neutron therapy.

For the 2015 update, the NCCN H&N Cancers Panel removed recommendations for neutron therapy for salivary gland cancers from the pathways because of the diminishing demand and closure of all but one center in the United States (see SALI-A, page 849). Although the clinical value of neutron therapy for selected patients is recognized, there are lingering toxicity concerns and the NCCN H&N Cancers Guidelines are meant to apply to recommendations that can be distributed to more than 5% of the eligible patients. Overall, the use of neutron therapy has lost traction over the years because of cost and toxicity considerations, and a lack of widely accepted clinical applications based on the limited amount of randomized trial data that remain specific to salivary gland cancers.

### Proton Therapy

Clinicians have long hoped that charged particle therapy, such as protons and carbon ions, would improve the local control of tumors while sparing adjacent normal structures from unnecessary radiation. Protons and carbon ions exhibit a defined Bragg peak of ionization.<sup>40</sup> The proton or carbon ion dose in front of the peak is notably lower, with a very pronounced and rapid falloff of dose after the peak, whereas the megavoltage photon-based therapy (as used in IMRT) and neutrons do not have this unique property.<sup>11</sup> Photon beams deliver relatively higher doses of “falloff” radiation along the beam path, whereas protons or carbon ions “stop” following the peak. The proton or carbon ion beam energy can be modulated so that the peak is sustained at all of the desired depths of penetration across the tumor while minimizing the dose to the immediately adjacent normal tissue. This is accomplished by using a scattered broad beam, with range modulation and a range compensator that conforms the dose to the distal edge of the tumor but increases the relative dose to the organs proximal to the tumor. More recently, in some centers, the energy of the beams is modulated electronically to treat the tumor layer by layer from distal edge to proximal edge while using magnets to scan the beam (discrete spots or continuous lines) throughout the tumor (intensity-modulated proton beam therapy [IMPT], pencil beam scanning).<sup>40</sup>

Only a slight difference is detectable in the RBE between proton and photon therapy, typically set at 1.1. Theoretically, proton therapy should represent a 10% increase in the RBE. However, there are variations in the exact dose calculation with respect to tissue type. Furthermore, the application of these findings with respect to clinical treatment planning algorithms is controversial.<sup>41</sup> Although there is little gain in the RBE, the potential advantage of proton therapy derives from the superior dose distributions obtained, with a decrease of the incidental dose delivered to adjacent normal tissues.<sup>11</sup> The hope is that these

sharper dose distributions might translate into reduced side effects in the normal tissues. In certain situations, these sharper dose distributions might be used to facilitate dose escalation to the tumor while delivering doses to the normal tissues similar to those given with photon-based therapy. The exploitation of the physical dose distribution is the driving force behind the enthusiasm for proton and carbon ion therapies. However, carbon ion therapy offers an additional opportunity to exploit an increased RBE and a dose distribution advantage (see “Carbon Ion Therapy,” facing page).<sup>42</sup>

At present, proton therapy is the predominant particle therapy under active clinical investigation in the United States.<sup>25,43–45</sup> Proton therapy has been used to treat oropharyngeal cancers, sinonasal malignancies, and mucosal melanomas, although the clinical data are best established for ocular melanomas and chordomas.<sup>46–51</sup> Single-institution outcome data have been reported for these H&N cancers,<sup>43,47–49,52,53</sup> but the literature does not easily allow direct comparisons between proton therapy and IMRT; historical comparisons warrant cautious interpretation, because improvements in diagnosis and staging evaluations may lead to improvements in reported outcomes independent of therapy. Mindful of these caveats, a recent systematic review and meta-analysis of noncomparative observation studies concluded that patients with malignant diseases of the nasal cavity and paranasal sinuses who received proton therapy seemed to have better outcomes than those receiving photon therapy.<sup>54</sup> A review of proton therapy in patients with H&N cancers was recently published that included 14 retrospective reviews and 4 prospective nonrandomized studies.<sup>25</sup> The 2- to 5-year local control rates were as low as 17.5% for T4 or recurrent paranasal sinus cancers and as high as 95% in other types of tumors.

In older institutional reports, outcomes for proton therapy have been reported for large unresectable H&N cancers, oropharyngeal cancers, sinonasal malignancies, chordomas, and sarcomas of the skull base.<sup>25,53,55–59</sup> For example, proton therapy was used for locally advanced sinonasal malignancies in 102 patients; disease-free survival rates were 49% to 90% at 5 years, depending on whether patients had partial or complete resection.<sup>60</sup> In comparison, conventional RT with photons has been reported to yield disease-free survival rates of 54% in patients with sinonasal malignancies.<sup>61,62</sup> In an older series, more than 500 patients with chordoma and chondrosarcoma were treated with proton therapy, and relapse-free survival rates were reported to be 73% and 98%, respectively, at 5 years, which is considered to be promising in these challenging disease types.<sup>53</sup> These older data from proton therapy were generated in the absence of sophisticated treatment planning and delivery tools currently available, such as IMPT planning systems, on-board image guidance, and technical solutions for motion management.<sup>25,63,64</sup>

Occasional fatal outcomes have been reported with proton therapy, including 3 deaths secondary to brainstem injury.<sup>53,57,65</sup> A recent report from Japan described long-term toxicities after proton therapy in 90 patients with nasal cavity, paranasal sinus, or skull base malignancies.<sup>52</sup> Late toxicities reached grade 3 in 17 patients (19%) and grade 4 in 6 patients (7%) (encephalomyelitis infection in 2 patients, optic nerve disorder in 4 patients). This rate of grade 3 to 4 late toxicity with protons (19%) was similar to the rate reported for conventional RT with photons (16%).<sup>61</sup> Other clinicians have reported low rates of serious

toxicities when using strict dose limits for proton therapy.<sup>47,66</sup> Proton therapy has typically been used to treat patients with the most challenging disease, for which other RT options were not felt to be safe or of any benefit.<sup>47,50,67</sup> Therefore, an accurate comparison of benefits would ideally take place in the controlled setting of randomized clinical trials. An alternative approach may be to develop prospectively maintained databases to raise the quality of institutional reports of clinical experiences.<sup>53</sup> Because of the current lack of data supporting clear or unique indications in H&N cancers for proton therapy, and the limited number of patients who may gain access to this treatment, specific recommendations for proton therapy have yet to be elucidated in the NCCN Guidelines for H&N Cancers.

### Carbon Ion Therapy

Carbon ion therapy (also known as *carbon ion RT*, *heavy ion therapy*) uses particles that are more massive than protons or neutrons. The high LET that occurs with carbon ion therapy can precisely target tumors and spare surrounding normal tissue due to the Bragg peak effect (see “Proton Therapy,” page 851).<sup>40</sup> Research using carbon ion therapy is ongoing outside of the United States.<sup>68–72</sup> Currently, there is no carbon ion facility in the United States, although public funding has been designated for early developmental efforts.<sup>29</sup> Because of its higher RBE, carbon ion therapy is thought to be promising for tumors traditionally considered resistant to standard RT. Some relatively large institutional case series have reported outcomes in patients with chordomas and chondrosarcomas of the skull base, mucosal melanomas, adenoid cystic carcinomas, salivary gland tumors, and squamous cell carcinomas of the H&N.<sup>71,72</sup> The optimization of carbon ion fractionation schemes and the degree to which carbon ions may be used as a supplement to photon-based RT are areas that require additional controlled investigations. Critical factors, such as accounting for tissue heterodensity and the radiobiological impact of these ions in normal tissues, need further clinical validation. However, even in the limited reports of these institutional experiences, the outcomes are encouraging.<sup>25,69</sup>

Because of the sharp dose distributions, high RBE, and limitations on this very expensive resource, carbon ions have frequently been used as a boost to photon-based therapy or over a shortened treatment time frame. A comprehensive review of the 20-year experience in Chiba, Japan was recently published; one of the major recommendations was the exploration of shorter treatment schedules for H&N cancers, such as 16 fractions.<sup>71</sup> The German experience with an intensity-controlled raster scanning technique developed at the Heidelberg Ion Therapy Center was reported in 118 patients. In these patients with H&N cancers who received photon-based therapy with carbon ion boost, the rate of grade 3 toxicities was less than 5%.<sup>72</sup> In the United States, carbon ion therapy is not yet reimbursable and, because of the lack of access, the NCCN Guidelines for H&N Cancers do not contain specific recommendations for carbon ion therapy.

### Summary

These NCCN Guidelines Insights focus on recent updates to the 2015 NCCN Guidelines for H&N Cancers. These Insights describe the major types of particle therapy that may be used to treat H&N cancers, such as proton, neutron, and carbon ion therapy, in contrast to



traditional RT with photons (x-rays). Research is ongoing regarding the different types of particle therapy, with the goal of increasing the tumoricidal effect and/or reducing long-term side effects from RT. Particle therapy is an exciting area of exploration but requires careful evaluation to determine its true clinical benefit. New and exciting advances in RT, such as particle therapy, have initially generated great enthusiasm; however, without robust, well-controlled data to support an advantage in long-term survival and/or toxicity reduction, some of these technologies have lost traction, especially because of the cost. Lessons have been learned from the early neutron experience that can be used to advance current research.

For the 2015 update, the NCCN H&N Cancers Panel agreed to remove the specific recommendations for neutron therapy for salivary gland cancers because of the limited availability and clinical application of this technology, and concerns that the toxicity of neutron therapy may offset potential disease control advantages (see SALI-A, page 849). Although the clinical value of neutron therapy is recognized for selected patients with salivary gland cancers, the NCCN Guidelines for H&N Cancers are meant to be generalizable to greater than 5% of the eligible population. For this reason, specific recommendations for proton and carbon ion therapy also are not currently specified in the guidelines. In regard to the current high level of interest in proton and/or carbon ion therapies, either a potential decrease in treatment toxicity or a safe escalation of the total dose of radiotherapy for certain malignancies would be a worthy goal. Nonetheless, it is important to note that other ongoing, less-costly clinical trials are addressing the safety and efficacy of decreasing the total dose of standard radiotherapy in combination with surgery, concurrent chemotherapy, or induction chemotherapy, with the goal of mitigating late toxicities in patients who have HPV-associated H&N cancers (ECOG 3311, NRG-HN002, ECOG 1308). Biologically based strategies may also be integrated into toxicity reduction; for instance, a national nasopharyngeal cancer trial uses a biologic marker (Epstein-Barr virus serology) to tailor adjuvant treatment for individual patients, thus reducing their overall multimodality-induced toxicity burden (NRG-HN001). Higher quality data for evaluating proton therapy will soon be generated. Large-scale randomized clinical trials of proton therapy in glioblastoma and non-small cell lung cancer (NRG-BN001, RTOG 1308) are ongoing and are expected to advance understanding of the role of proton therapy in the treatment of clinically challenging malignancies. Public funding support for comparative studies of particle and photon therapies will assist in rigorous assessment of these technologies in the future.

## Acknowledgments

The authors wish to thank Donna M. Powell, MS, CMD, RT(T), Oncology Scientist, Radiation Oncology Programs at NCCN, for reviewing these NCCN Guidelines Insights.

Supported by an educational grant from Eisai; a contribution from Exelixis Inc.; educational grants from Bristol-Myers Squibb, Genentech BioOncology, Merck, Novartis Oncology, Novocure; and by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

## References

1. Mehanna H, Paleri V, West CM, Nutting C. Head and neck cancer—part 1: epidemiology, presentation, and prevention. *BMJ*. 2010; 341:c4684. [PubMed: 20855405]

2. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. *J Clin Oncol*. 2011; 29:4294–4301. [PubMed: 21969503]
3. Jemal A, Simard EP, Dorell C, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. *J Natl Cancer Inst*. 2013; 105:175–201. [PubMed: 23297039]
4. Chaturvedi AK, Anderson WF, Lortet-Tieulent J, et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. *J Clin Oncol*. 2013; 31:4550–4559. [PubMed: 24248688]
5. Gillison ML, Alemany L, Snijders PJ, et al. Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. *Vaccine*. 2012; 30(Suppl 5):F34–54. [PubMed: 23199965]
6. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. *J Natl Cancer Inst*. 2000; 92:709–720. [PubMed: 10793107]
7. Cohan DM, Popat S, Kaplan SE, et al. Oropharyngeal cancer: current understanding and management. *Curr Opin Otolaryngol Head Neck Surg*. 2009; 17:88–94. [PubMed: 19373958]
8. Centers for Disease C, Prevention. Human papillomavirus-associated cancers - United States, 2004-2008. *MMWR Morb Mortal Wkly Rep*. 2012; 61:258–261. [PubMed: 22513527]
9. Nutting CM, Morden JP, Harrington KJ, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. *Lancet Oncol*. 2011; 12:127–136. [PubMed: 21236730]
10. Tribius S, Bergelt C. Intensity-modulated radiotherapy versus conventional and 3D conformal radiotherapy in patients with head and neck cancer: is there a worthwhile quality of life gain? *Cancer Treat Rev*. 2011; 37:511–519. [PubMed: 21324605]
11. Ratko, TA.; Douglas, GW.; de Souza, JA., et al. Radiotherapy Treatments for Head and Neck Cancer Update. Rockville, MD: Agency for Healthcare Research and Quality (US); 2014.
12. Hunter KU, Schipper M, Feng FY, et al. Toxicities affecting quality of life after chemo-IMRT of oropharyngeal cancer: prospective study of patient-reported, observer-rated, and objective outcomes. *Int J Radiat Oncol Biol Phys*. 2013; 85:935–940. [PubMed: 23040224]
13. Lohia S, Rajapurkar M, Nguyen SA, et al. A comparison of outcomes using intensity-modulated radiation therapy and 3-dimensional conformal radiation therapy in treatment of oropharyngeal cancer. *JAMA Otolaryngol Head Neck Surg*. 2014; 140:331–337. [PubMed: 24557509]
14. Kam MK, Leung SF, Zee B, et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. *J Clin Oncol*. 2007; 25:4873–4879. [PubMed: 17971582]
15. Baxi SS, Sher DJ, Pfister DG. Value considerations in the treatment of head and neck cancer: radiation, chemotherapy, and supportive care. *Am Soc Clin Oncol Educ Book*. 2014:e296–303. [PubMed: 24857116]
16. Rosenthal DI, Chambers MS, Fuller CD, et al. Beam path toxicities to non-target structures during intensity-modulated radiation therapy for head and neck cancer. *Int J Radiat Oncol Biol Phys*. 2008; 72:747–755. [PubMed: 18455324]
17. Kocak-Uzel E, Gunn GB, Colen RR, et al. Beam path toxicity in candidate organs-at-risk: assessment of radiation emetogenesis for patients receiving head and neck intensity modulated radiotherapy. *Radiother Oncol*. 2014; 111:281–288. [PubMed: 24746582]
18. Eisbruch A, Schwartz M, Rasch C, et al. Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: which anatomic structures are affected and can they be spared by IMRT? *Int J Radiat Oncol Biol Phys*. 2004; 60:1425–1439. [PubMed: 15590174]
19. Brown PD, Foote RL, McLaughlin MP, et al. A historical prospective cohort study of carotid artery stenosis after radiotherapy for head and neck malignancies. *Int J Radiat Oncol Biol Phys*. 2005; 63:1361–1367. [PubMed: 16169673]
20. Citrin D, Mansueti J, Likhacheva A, et al. Long-term outcomes and toxicity of concurrent paclitaxel and radiotherapy for locally advanced head-and-neck cancer. *Int J Radiat Oncol Biol Phys*. 2009; 74:1040–1046. [PubMed: 19117692]

21. Forastiere AA, Zhang Q, Weber RS, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. *J Clin Oncol.* 2013; 31:845–852. [PubMed: 23182993]
22. Awan MJ, Mohamed AS, Lewin JS, et al. Late radiation-associated dysphagia (late-RAD) with lower cranial neuropathy after oropharyngeal radiotherapy: a preliminary dosimetric comparison. *Oral Oncol.* 2014; 50:746–752. [PubMed: 24906528]
23. Sharma J, Dougherty AH. Recurrent syncope in a cancer patient: a case report and review of the literature. *Cardiol Res Pract.* 2011; 2011:678237. [PubMed: 21559220]
24. Cooper JS, Zhang Q, Pajak TF, et al. Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. *Int J Radiat Oncol Biol Phys.* 2012; 84:1198–1205. [PubMed: 22749632]
25. Holliday EB, Frank SJ. Proton radiation therapy for head and neck cancer: a review of the clinical experience to date. *Int J Radiat Oncol Biol Phys.* 2014; 89:292–302. [PubMed: 24837890]
26. Trikalinos, TA.; Terasawa, T.; Ip, S., et al. *Particle Beam Radiation Therapies for Cancer.* Rockville, MD: Agency for Healthcare Research and Quality (US); 2009.
27. Mitin T, Zietman AL. Promise and pitfalls of heavy-particle therapy. *J Clin Oncol.* 2014; 32:2855–2863. [PubMed: 25113772]
28. Johnstone PA, Kerstiens J. Doing poorly by doing good: the bottom line of proton therapy for children. *J Am Coll Radiol.* 2014; 11:995–997. [PubMed: 24881504]
29. Schlaff CD, Krauze A, Belard A, et al. Bringing the heavy: carbon ion therapy in the radiobiological and clinical context. *Radiat Oncol.* 2014; 9:88. [PubMed: 24679134]
30. Catterall M. First randomized clinical trial of fast neutrons compared with photons in advanced carcinoma of the head and neck. *Clin Otolaryngol Allied Sci.* 1977; 2:359–372. [PubMed: 413678]
31. Blake PR, Catterall M, Errington RD. Treatment of malignant melanoma by fast neutrons. *Br J Surg.* 1985; 72:517–519. [PubMed: 3926037]
32. Maor MH, Errington RD, Caplan RJ, et al. Fast-neutron therapy in advanced head and neck cancer: a collaborative international randomized trial. *Int J Radiat Oncol Biol Phys.* 1995; 32:599–604. [PubMed: 7790244]
33. MacDougall RH, Orr JA, Kerr GR, Duncan W. Fast neutron treatment for squamous cell carcinoma of the head and neck: final report of Edinburgh randomised trial. *BMJ.* 1990; 301:1241–1242. [PubMed: 2125513]
34. Laramore GE, Krall JM, Griffin TW, et al. Neutron versus photon irradiation for unresectable salivary gland tumors: final report of an RTOG-MRC randomized clinical trial. *Radiation Therapy Oncology Group. Medical Research Council Int J Radiat Oncol Biol Phys.* 1993; 27:235–240.
35. Griffin BR, Laramore GE, Russell KJ, et al. Fast neutron radiotherapy for advanced malignant salivary gland tumors. *Radiother Oncol.* 1988; 12:105–111. [PubMed: 3406455]
36. Stannard C, Vernimmen F, Carrara H, et al. Malignant salivary gland tumours: can fast neutron therapy results point the way to carbon ion therapy? *Radiother Oncol.* 2013; 109:262–268. [PubMed: 24044797]
37. Glaholm J, Harmer C. Soft-tissue sarcoma: neutrons versus photons for post-operative irradiation. *Br J Radiol.* 1988; 61:829–834. [PubMed: 3140995]
38. Withers HR, Thames HD, Peters LJ. Biological bases for high RBE values for late effects of neutron irradiation. *Int J Radiat Oncol Biol Phys.* 1982; 8:2071–2076. [PubMed: 6819269]
39. Glenny AM, Furness S, Worthington HV, et al. Interventions for the treatment of oral cavity and oropharyngeal cancer: radiotherapy. *Cochrane Database Syst Rev.* 2010:CD006387. [PubMed: 21154367]
40. Demizu Y, Fujii O, Iwata H, Fuwa N. Carbon ion therapy for early-stage non-small-cell lung cancer. *Biomed Res Int.* 2014; 2014:727962. [PubMed: 25295269]
41. Gerweck LE, Kozin SV. Relative biological effectiveness of proton beams in clinical therapy. *Radiother Oncol.* 1999; 50:135–142. [PubMed: 10368035]
42. Suit H, DeLaney T, Goldberg S, et al. Proton vs carbon ion beams in the definitive radiation treatment of cancer patients. *Radiother Oncol.* 2010; 95:3–22. [PubMed: 20185186]

43. Hutcheson K, Lewin J, Garden A, et al. Early experience with IMPT for the treatment of oropharyngeal tumors: Acute toxicities and swallowing-related outcomes. *Int J Radiat Oncol Biol Phys.* 2013; 87:S604.
44. Frank, SJ. [Accessed April 27, 2015] Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT). 2015. Available at: <http://clinicaltrials.gov/show/NCT01893307>
45. Miller RC, Lodge M, Murad MH, Jones B. Controversies in clinical trials in proton radiotherapy: the present and the future. *Semin Radiat Oncol.* 2013; 23:127–133. [PubMed: 23473690]
46. Zenda S, Kawashima M, Nishio T, et al. Proton beam therapy as a nonsurgical approach to mucosal melanoma of the head and neck: a pilot study. *Int J Radiat Oncol Biol Phys.* 2011; 81:135–139. [PubMed: 20950948]
47. Fukumitsu N, Okumura T, Mizumoto M, et al. Outcome of T4 (International Union Against Cancer Staging System, 7th edition) or recurrent nasal cavity and paranasal sinus carcinoma treated with proton beam. *Int J Radiat Oncol Biol Phys.* 2012; 83:704–711. [PubMed: 22099036]
48. Demizu Y, Fujii O, Terashima K, et al. Particle therapy for mucosal melanoma of the head and neck. A single-institution retrospective comparison of proton and carbon ion therapy. *Strahlenther Onkol.* 2014; 190:186–191. [PubMed: 24362502]
49. Fuji H, Yoshikawa S, Kasami M, et al. High-dose proton beam therapy for sinonasal mucosal malignant melanoma. *Radiat Oncol.* 2014; 9:162. [PubMed: 25056641]
50. Allen AM, Pawlicki T, Dong L, et al. An evidence based review of proton beam therapy: the report of ASTRO's emerging technology committee. *Radiother Oncol.* 2012; 103:8–11. [PubMed: 22405807]
51. Levin WP, Kooy H, Loeffler JS, DeLaney TF. Proton beam therapy. *Br J Cancer.* 2005; 93:849–854. [PubMed: 16189526]
52. Zenda S, Kawashima M, Arahira S, et al. Late toxicity of proton beam therapy for patients with the nasal cavity, para-nasal sinuses, or involving the skull base malignancy: importance of long-term follow-up. *Int J Clin Oncol.* 2014
53. Munzenrider JE, Liebsch NJ. Proton therapy for tumors of the skull base. *Strahlenther Onkol.* 1999; 175(Suppl 2):57–63. [PubMed: 10394399]
54. Patel SH, Wang Z, Wong WW, et al. Charged particle therapy versus photon therapy for paranasal sinus and nasal cavity malignant diseases: a systematic review and meta-analysis. *Lancet Oncol.* 2014; 15:1027–1038. [PubMed: 24980873]
55. Tokuyue K, Akine Y, Kagei K, et al. Proton therapy for head and neck malignancies at Tsukuba. *Strahlenther Onkol.* 2004; 180:96–101. [PubMed: 14762662]
56. Noel G, Habrand JL, Jauffret E, et al. Radiation therapy for chordoma and chondrosarcoma of the skull base and the cervical spine. Prognostic factors and patterns of failure *Strahlenther Onkol.* 2003; 179:241–248. [PubMed: 12707713]
57. Santoni R, Liebsch N, Finkelstein DM, et al. Temporal lobe (TL) damage following surgery and high-dose photon and proton irradiation in 96 patients affected by chordomas and chondrosarcomas of the base of the skull. *Int J Radiat Oncol Biol Phys.* 1998; 41:59–68. [PubMed: 9588918]
58. Slater JD, Yonemoto LT, Mantik DW, et al. Proton radiation for treatment of cancer of the oropharynx: early experience at Loma Linda University Medical Center using a concomitant boost technique. *Int J Radiat Oncol Biol Phys.* 2005; 62:494–500. [PubMed: 15890592]
59. Chan A, Liebsch L, Deschler D, et al. Proton radiotherapy for T4 nasopharyngeal carcinoma [abstract]. *J Clin Oncol.* 2004; 22(Suppl) Abstract 5574.
60. Resto VA, Chan AW, Deschler DG, Lin DT. Extent of surgery in the management of locally advanced sinonasal malignancies. *Head Neck.* 2008; 30:222–229. [PubMed: 17902164]
61. Chen AM, Daly ME, Bucci MK, et al. Carcinomas of the paranasal sinuses and nasal cavity treated with radiotherapy at a single institution over five decades: are we making improvement? *Int J Radiat Oncol Biol Phys.* 2007; 69:141–147. [PubMed: 17459609]
62. Hoppe BS, Stegman LD, Zelefsky MJ, et al. Treatment of nasal cavity and paranasal sinus cancer with modern radiotherapy techniques in the postoperative setting—the MSKCC experience. *Int J Radiat Oncol Biol Phys.* 2007; 67:691–702. [PubMed: 17161557]

63. Frank SJ, Cox JD, Gillin M, et al. Multifield optimization intensity modulated proton therapy for head and neck tumors: a translation to practice. *Int J Radiat Oncol Biol Phys.* 2014; 89:846–853. [PubMed: 24867532]
64. Stenecker M, Lomax A, Schneider U. Intensity modulated photon and proton therapy for the treatment of head and neck tumors. *Radiother Oncol.* 2006; 80:263–267. [PubMed: 16916557]
65. Zenda S, Kohno R, Kawashima M, et al. Proton beam therapy for unresectable malignancies of the nasal cavity and paranasal sinuses. *Int J Radiat Oncol Biol Phys.* 2011; 81:1473–1478. [PubMed: 20961697]
66. Fitzek MM, Thornton AF, Varvares M, et al. Neuroendocrine tumors of the sinonasal tract. Results of a prospective study incorporating chemotherapy, surgery, and combined proton-photon radiotherapy. *Cancer.* 2002; 94:2623–2634. [PubMed: 12173330]
67. Patel S, Kostaras X, Parliament M, et al. Recommendations for the referral of patients for proton-beam therapy, an Alberta Health Services report: a model for Canada? *Curr Oncol.* 2014; 21:251–262. [PubMed: 25302033]
68. Mizoe JE, Hasegawa A, Jingu K, et al. Results of carbon ion radiotherapy for head and neck cancer. *Radiother Oncol.* 2012; 103:32–37. [PubMed: 22321201]
69. Schulz-Ertner D, Nikoghosyan A, Jakel O, et al. Feasibility and toxicity of combined photon and carbon ion radiotherapy for locally advanced adenoid cystic carcinomas. *Int J Radiat Oncol Biol Phys.* 2003; 56:391–398. [PubMed: 12738314]
70. Mizoe JE, Tsujii H, Kamada T, et al. Dose escalation study of carbon ion radiotherapy for locally advanced head-and-neck cancer. *Int J Radiat Oncol Biol Phys.* 2004; 60:358–364. [PubMed: 15380567]
71. Kamada T, Tsujii H, Blakely EA, et al. Carbon ion radiotherapy in Japan: an assessment of 20 years of clinical experience. *Lancet Oncol.* 2015; 16:e93–e100. [PubMed: 25638685]
72. Rieken S, Habermehl D, Nikoghosyan A, et al. Assessment of early toxicity and response in patients treated with proton and carbon ion therapy at the Heidelberg ion therapy center using the raster scanning technique. *Int J Radiat Oncol Biol Phys.* 2011; 81:e793–801. [PubMed: 21300464]

## NCCN: Continuing Education

### Accreditation Statement

This activity is designated to meet the educational needs of physicians, nurses, and pharmacists involved in the management of patients with cancer. There is no fee for this article. The National Comprehensive Cancer Network (NCCN) is accredited by the ACCME to provide continuing medical education for physicians. NCCN designates this journal-based CE activity for a maximum of 1.0 *AMA PRA Category 1 Credit*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NCCN is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

NCCN designates this educational activity for a maximum of 1.0 contact hour. Accreditation as a provider refers to recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity. Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity.

National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. NCCN designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of continuing education credit in states that recognize ACPE accredited providers. This is a knowledge-based activity. UAN: 0836-0000-15-008-H01P

All clinicians completing this activity will be issued a certificate of participation. To participate in this journal CE activity: 1) review the learning objectives and author disclosures; 2) study the education content; 3) take the posttest with a 66% minimum passing score and complete the evaluation at <http://education.nccn.org/node/70211>; and 4) view/print certificate.

### Learning Objectives

Upon completion of this activity, participants will be able to:

- Integrate into professional practice the updates to the NCCN Guidelines for Head and Neck Cancers
- Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Head and Neck Cancers

### NCCN Categories of Evidence and Consensus

**Category 1:** Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

**Category 2A:** Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

**Category 2B:** Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

**Category 3:** Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations are category 2A unless otherwise noted.

Clinical trials: NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.